SCTB41 is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Sinocelltech Ltd.. Registered phases: Phase 1/2 and Phase 2/3. Conditions studied include NHL - Non-Hodgkin's Lymphoma; Double Blind; Advanced Malignant Solid Tumours.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07662395 | SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Double Blind |
Phase 2/3 | Recruiting |
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. (ClinicalTrials.gov ↗) Advanced Malignant Solid Tumours |
Phase 1/2 | Recruiting |
| NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗) NHL - Non-Hodgkin's Lymphoma |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| NHL - Non-Hodgkin's Lymphoma | 1 |
| Double Blind | 1 |
| Advanced Malignant Solid Tumours | 1 |
| Lead sponsor | Trials |
|---|---|
| Sinocelltech Ltd. | 3 |
| Register | SCTB41 trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SCTB41 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SCTB41 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.